Harbour BioMed announced the appointment of Atul Deshpande as Chief Strategy Officer and Head of U.S. Operations. Dr. Deshpande joins Harbour BioMed from Sanofi, where he served as Global Operations Lead of Sanofi Genzyme’s Dupixent® (dupilumab) franchise. During his tenure at Sanofi Genzyme, Dr. Deshpande delivered on roles with increasing responsibility from strategy to implementation. He was instrumental in establishing and executing global Dupixent launches in Atopic Dermatitis and Asthma. The company also announced the promotions of Dr. Xiaoxiang Chen, MD to Chief Development Officer, and Dr. Mai-Jing Liao, Ph.D., MBA to Chief Business Officer, effective immediately.